Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multi specific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421;

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio   Companies will develop a transition plan with the goal of returning full commercialization responsibilities to